ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Get Free Report) Director Patrick Walsh sold 3,973 shares of the business’s stock in a transaction dated Monday, May 11th. The stock was sold at an average price of $80.75, for a total transaction of $320,819.75. Following the completion of the transaction, the director directly owned 48,432 shares in the company, valued at $3,910,884. This trade represents a 7.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.
ANI Pharmaceuticals Stock Performance
Shares of NASDAQ:ANIP traded up $1.38 during midday trading on Wednesday, reaching $80.88. The company had a trading volume of 308,836 shares, compared to its average volume of 382,710. The company’s 50 day moving average price is $77.19 and its 200 day moving average price is $80.60. The company has a current ratio of 3.12, a quick ratio of 2.52 and a debt-to-equity ratio of 1.06. The stock has a market cap of $1.81 billion, a P/E ratio of 20.48 and a beta of 0.46. ANI Pharmaceuticals, Inc. has a 52-week low of $56.71 and a 52-week high of $99.50.
ANI Pharmaceuticals (NASDAQ:ANIP – Get Free Report) last issued its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.77. The company had revenue of $237.46 million for the quarter, compared to the consensus estimate of $207.63 million. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The firm’s quarterly revenue was up 20.5% on a year-over-year basis. During the same period in the previous year, the firm earned $1.70 EPS. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. As a group, sell-side analysts anticipate that ANI Pharmaceuticals, Inc. will post 7.73 EPS for the current fiscal year.
Institutional Investors Weigh In On ANI Pharmaceuticals
Wall Street Analysts Forecast Growth
A number of brokerages recently weighed in on ANIP. Zacks Research raised shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Wednesday, April 15th. Wall Street Zen raised shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Guggenheim upped their price objective on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a report on Friday, January 16th. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $107.33.
View Our Latest Stock Report on ANI Pharmaceuticals
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.
ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.
Read More
- Five stocks we like better than ANI Pharmaceuticals
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
